6169 UK GAAP 2004. qxd 7 12 05 1:57 PM Page 10 Shire Pharmaceuticals Group plc The Board of Directors The Board of Directors Dr James Cavanaugh 68 Mr Matthew Emmens 53 Mr Angus Russell 49 Dr Barry Price 61 Chairman Chief Executive Officer Chief Financial Officer and Non-executive Director Dr James Cavanaugh joined Matthew Emmens joined Shire Executive Vice President Dr Barry Price joined the Board the Board of Shire on 24 March as Chief Executive Officer of Global Finance of Shire on 16 January 1996 1997 and was appointed as and member of the Board of Angus Russell joined Shire having spent 28 years with Chairman with effect from Shire on 12 March 2003. in 1999 as Chief Financial Glaxo holding a succession 11 May 1999.
Dr Cavanaugh is Mr Emmens began his career Officer.
Mr Russell previously of executive positions with a general partner of HealthCare in international pharmaceuticals worked for ICI, Zeneca and Glaxo Group Research.
He is Partners, the General Partner of with Merck & Co, Inc. in 1974.
His last position Chairman of Antisoma plc and HealthCare Ventures, a venture There he held a wide range was Vice President Corporate also Biowisdom Ltd and is capital fund devoted exclusively of sales, marketing and Finance at AstraZeneca plc.
on the board of directors of to healthcare.
Formerly he administrative positions before Prior to this, he held a number Pharmagene plc.
Dr Price was was President of SmithKline volunteering in 1992 to help of positions within the Zeneca Chairman of the Remuneration & French Laboratories, the establish Astra Merck, the Group from 1993 until 1999 Committee and a member of US pharmaceutical division joint venture between Merck including Group Treasurer, and both the Audit Committee and of SmithKline Beecham and Astra AB of Sweden.
before that in ICI from 1980 the Nomination Committee in Corporation.
Prior to that, he He later became President until 1992.
Dr Price is Shires senior was President of SmithKline and Chief Executive Officer.
chartered accountant, having non-executive Director.
Beecham Corporations In 1999 he joined Merck qualified with Coopers & clinical laboratory business KGaA and established EMD Lybrand, and is a fellow of and, before that, President Pharmaceuticals, the the Association of Corporate of Allergan International.
Prior companys US prescription Treasurers.
Mr Russell is a to his industry experience, pharmaceutical business.
member of the Executive Dr Cavanaugh served as Deputy He was later promoted to Committee.
He is also a nonAssistant to the President of the President of the global executive Director of the City US on the White House Staff prescription business and lived of London Investment Trust plc.
Mr Emmens is a executive Chairman of Diversa graduate of Fairleigh Dickinson Corporation and Vicuron, Inc. University New Jersey, USA and a non-executive director of with a BS in Business MedImmune Inc. and Advancis Management.
is a member of the Board Dr Cavanaugh was a member of Directors, and Chairman of the Remuneration Committee of the Executive and Portfolio until April 2004 and a member Review Committees.
of the Audit Committee until November 2004.
He acted as Chairman of the Nomination Committee throughout 2004.
10 6169 UK GAAP 2004. qxd 7 12 05 1:57 PM Page 11 Shire Pharmaceuticals Group plc The Board of Directors The Hon James Grant, Mr Ronald Nordmann 63 Mr Robin Buchanan 52 Mr David Kappler 57 P. C. C. M. Q. C. 67 Non-executive Director Non-executive Director Non-executive Director Non-executive Director Ronald Nordmann joined the Robin Buchanan joined the David Kappler joined the Board The Hon James Grant joined Board of Shire on 23 December Board of Shire on 30 July of Shire as a non-executive the Board of Shire on 11 May 1999 having previously served 2003.
He is the Senior Partner Director on 5 April 2004.
Mr 2001 as a non-executive as a non-executive director of the UK operations and Kappler retired as Chief Financial Director.
Prior to its merger of Roberts Pharmaceutical director of the global business Officer of Cadbury Schweppes with Shire, Mr Grant had been Corporation since May 1999. consultants Bain & Company plc, the FTSE and NYSE listed a director of BioChem Pharma Mr Nordmann has been a Inc. and a member of the firms global confectionery and Inc. since 1986.
He is a partner financial analyst in healthcare worldwide management beverages group in April 2004, and Chair Emeritus with the equities since 1971.
Prior to his career having held that position since law firm Stikeman Elliott in September 1994 to January with Bain & Company Inc. 1995.
He worked for the Montreal.
Mr Grant sits on the 2000 he was an analyst Mr Buchanan worked for Cadbury Schweppes group boards of two Canadian public and partner at Deerfield American Express International between 1965 and 1984 and corporations, in addition to Management.
He is currently Banking Corporation in New rejoined it in 1989, following the other private corporations and Co-President of Global Health York, McKinsey & Company acquisition of the Trebor Group foundations and councils that Associates and has held senior and Deloitte & Touche where of which he was Financial are not-for-profit organisations.
positions with PaineWebber, he qualified as a chartered Director.
From 1989 to 1995 He attended McGill University, Oppenheimer & Co. accountant FCA.
Mr he held a number of senior receiving a BA in arts in 1958 F Eberstadt & Co. and Buchanan currently serves positions in Cadbury and a BCL in Law in 1961.
Warner-Chilcott Laboratories, as a non-executive director Schweppes, including Director Mr Grant was a member of the a division of Warner-Lambert.
Mr Kappler Nomination Committee in 2004.
Mr Nordmann received his Mr Buchanan has an MBA with has served on a number of other undergraduate degree from Distinction Baker Scholar boards around the world in The Johns Hopkins University from Harvard Business School.
which Cadbury Schweppes held and an MBA from Fairleigh Mr Buchanan was a member of interests.
He was a director of Dickinson University.
Mr the Remuneration Committee Camelot Group plc from 1996 Nordmann is also a Director of in 2004. to 2002 and he currently serves Guilford Pharmaceuticals Inc. as a non-executive director and Neurochem Inc. and Par Chairman of the Audit Committee Pharmaceuticals, Inc. Mr at HMV Group plc and Nordmann was Chairman of Intercontinental Hotels Group the Audit Committee until July plc.
Additionally, he is non- 2004 and he remains a member executive Chairman at Premier of that Committee.
Mr Kappler is a fellow a member of the Nomination of the Chartered Institute of Committee throughout 2004 Management Accountants.
Mr and he became a member of Kappler became a member of the Remuneration Committee Shires Audit Committee upon in April 2004. his appointment to the Board and took over the Chairmanship of that Committee in July 2004.
